Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis

In addition to dysregulated JAK/STAT signaling, activation of the AKT/mTOR pathway occurs in myelofibrosis, a myeloproliferative neoplasm with no approved therapies. We conducted a phase 1/2 study with everolimus, an mTOR inhibitor, in 39 high- or intermediate-risk primary or postpolycythemia vera/p...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Guglielmelli, Paola, Barosi, Giovanni, Rambaldi, Alessandro, Marchioli, Roberto, Masciulli, Arianna, Tozzi, Lorenzo, Biamonte, Flavia, Bartalucci, Niccolò, Gattoni, Elisabetta, Lupo, Maria Letizia, Finazzi, Guido, Pancrazzi, Alessandro, Antonioli, Elisabetta, Susini, Maria Chiara, Pieri, Lisa, Malevolti, Elisa, Usala, Emilio, Occhini, Ubaldo, Grossi, Alberto, Caglio, Silvia, Paratore, Simona, Bosi, Alberto, Barbui, Tiziano, Vannucchi, Alessandro M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2011
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3365876/
https://ncbi.nlm.nih.gov/pubmed/21725052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-01-330563
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg